{
    "organizations": [],
    "uuid": "32ff92c603bcfe4b50c498bd60182b52c511ed87",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-newlink-genetics-outlines-2018-bus/brief-newlink-genetics-outlines-2018-business-priorities-idUSASB0C03C",
    "ord_in_thread": 0,
    "title": "BRIEF-Newlink Genetics Outlines 2018 Business Priorities",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Newlink Genetics Corp:\n* NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS\n* NEWLINK GENETICS CORP - ENDED 2017 WITH APPROXIMATELY $158 MILLION IN CASH AND CASH EQUIVALENTS\n* NEWLINK GENETICS - ENTERING 2018, HAVE ALIGNED BUSINESS AND INVESTMENTS TO DRIVE INDIGO301 AND OTHER HIGH-POTENTIAL DEVELOPMENT PROGRAMS\n* NEWLINK GENETICS CORP - ENROLL MAJORITY OF INDIGO301 TRIAL BY END OF 2018\n* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018\n* NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC CANCER EXPECTED 1H 2018\n* NEWLINK GENETICS CORP - PHASE 2 RANDOMIZED ASTRAZENECA COLLABORATION IN PANCREATIC CANCER TO INITIATE 1H 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:13:00.000+02:00",
    "crawled": "2018-01-09T16:53:26.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "newlink",
        "genetics",
        "corp",
        "newlink",
        "genetics",
        "outline",
        "business",
        "priority",
        "support",
        "phase",
        "pivotal",
        "trial",
        "indoximod",
        "plus",
        "inhibitor",
        "newlink",
        "genetics",
        "corp",
        "ended",
        "approximately",
        "million",
        "cash",
        "cash",
        "equivalent",
        "newlink",
        "genetics",
        "entering",
        "aligned",
        "business",
        "investment",
        "drive",
        "indigo301",
        "development",
        "program",
        "newlink",
        "genetics",
        "corp",
        "enroll",
        "majority",
        "indigo301",
        "trial",
        "end",
        "newlink",
        "genetics",
        "corp",
        "phase",
        "result",
        "indoximod",
        "blockade",
        "advanced",
        "melanoma",
        "expected",
        "newlink",
        "genetics",
        "corp",
        "phase",
        "result",
        "indoximod",
        "pancreatic",
        "cancer",
        "expected",
        "1h",
        "newlink",
        "genetics",
        "corp",
        "phase",
        "randomized",
        "astrazeneca",
        "collaboration",
        "pancreatic",
        "cancer",
        "initiate",
        "1h",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}